OR WAIT null SECS
Buffers, stabilizers, and cryoprotectants play major roles in cell therapy formulations.
The success of mRNA-based vaccines paves the way for mRNA in oncology and beyond.
The authors give an overview of scaling approaches and present good scaling practices for the biopharma industry.
March 15, 2024
ProBioGen and Mapp Biopharmaceutical will use the former’s GlymaxX technology to develop a cell line for an afucosylated antibody that targets Marburg virus infection
March 13, 2024
Under a new agreement, Chime Biologics will manufacture Domain Therapeutics’ antibody cancer immunotherapy candidate, DT-7012.
March 08, 2024
EMA has validated two MAAs submitted by AstraZeneca and Daiichi Sankyo for datopotamab deruxtecan in two types of cancer.
March 07, 2024
Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.
March 06, 2024
Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.
March 04, 2024
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
March 02, 2024
Despite a growing number of biosimilar approvals, market uptake remains a challenge.
Proprietary cell lines offer opportunities for achieving high AAV titers.
March 01, 2024
CordenPharma’s new starter kits are designed to enable effective formulation in the development of mRNA-based therapeutics.
February 29, 2024
Webinar Date/Time: Thu, Mar 28, 2024 11:00 AM EDT